Z92.21

Personal history of antineoplastic chemotherapy

## Overview of Personal History of Antineoplastic Chemotherapy The ICD-10 code Z92.21 is a specific status code used to document a patient's historical exposure to antineoplastic chemotherapy agents. In clinical practice, the documentation of this history is paramount, as many chemotherapeutic agents have long-term systemic effects that can influence patient health years or even decades after the conclusion of treatment. This code is intended for patients who have completed their chemotherapy regimen and are no longer actively receiving these specific agents for an active malignancy. It serves as a vital marker for clinicians to identify potential late-stage toxicities and to inform future treatment pathways. ### Clinical Significance and Long-Term Sequelae The clinical significance of a history of chemotherapy lies primarily in the risk of 'late effects'—side effects that appear months or years after treatment ends. Many classes of antineoplastic agents possess specific organ-toxic profiles. For example, anthracyclines (such as Doxorubicin) are known for cumulative, dose-dependent cardiotoxicity, which may eventually lead to congestive heart failure or cardiomyopathy. Platinum-based therapies (such as Cisplatin) are frequently associated with long-term nephrotoxicity, ototoxicity, and persistent peripheral neuropathy. Alkylating agents (such as Cyclophosphamide) are linked to an increased risk of secondary malignancies, particularly therapy-related myeloid neoplasms. Identifying Z92.21 in a medical record prompts the clinician to evaluate these specific organ systems during routine surveillance. ### Surveillance and Survivorship Care Patients with a history of chemotherapy require structured survivorship care. This involves not only monitoring for the recurrence of the primary malignancy but also proactive screening for secondary cancers and organ dysfunction. Monitoring protocols often include periodic echocardiography for those exposed to cardiotoxic agents, pulmonary function testing for those treated with bleomycin, and regular laboratory assessment of renal and hepatic function. Additionally, survivors may experience 'chemo brain' (cognitive impairment) or psychological distress, necessitating a multidisciplinary approach to care involving oncology, primary care, and specialized services. ### Impact on Clinical Decision-Making A documented history of antineoplastic chemotherapy significantly impacts current clinical decision-making. It influences the selection of future pharmacotherapy, as previous drug exposure may limit the lifetime cumulative dose allowed for certain agents or increase the likelihood of adverse drug-drug interactions. For instance, if a patient requires future surgery, a history of chemotherapy may indicate impaired wound healing or a higher risk of pulmonary complications if oxygen levels are not strictly managed. Furthermore, clinicians must be aware of the patient's potential for underlying bone marrow suppression or chronic immunosuppression when treating infections or prescribing other myelosuppressive medications.

Clinical Symptoms

  • Chronic fatigue
  • Peripheral neuropathy (numbness or tingling)
  • Cognitive impairment (difficulty concentrating or memory issues)
  • Shortness of breath (potential cardiotoxicity indicator)
  • Hearing loss or tinnitus
  • Early menopause or infertility
  • Reduced exercise tolerance
  • Chronic kidney disease manifestations
  • Increased susceptibility to infections
  • Persistent joint or muscle pain

Common Causes

  • History of solid organ malignancies (e.g., breast, lung, colorectal cancer)
  • History of hematologic malignancies (e.g., leukemia, lymphoma, myeloma)
  • Adjuvant chemotherapy administered after primary surgical intervention
  • Neoadjuvant chemotherapy administered to downstage a tumor before surgery
  • Palliative chemotherapy for previously managed metastatic disease
  • History of high-dose chemotherapy prior to bone marrow or stem cell transplant

Documentation & Coding Tips

Clearly distinguish between active treatment and personal history.

Example: Patient is a 65-year-old female with a personal history of stage II breast cancer, status post lumpectomy and completed adjuvant chemotherapy with AC-T (Adriamycin and Cytoxan) in 2018. Currently no evidence of disease. Today's visit focuses on long-term surveillance and management of chemotherapy-induced peripheral neuropathy in both feet. Risk adjustment reflects the complexity of managing chronic sequelae from past intensive curative treatments.

Billing Focus: The documentation specifies the completion date and the specific agents used, supporting the use of Z92.21 as a secondary code to explain current sequelae.

Document specific agents or classes of chemotherapy used to justify surveillance protocols.

Example: Assessment: History of antineoplastic chemotherapy (Z92.21) utilizing anthracyclines for DLBCL (diagnosed 2015). Given the risk of late-onset cardiomyopathy, a screening echocardiogram is ordered today. Patient also reports mild exertion dyspnea, evaluated under moderate MDM guidelines for established patients (99214).

Billing Focus: Linking the specific drug class (anthracyclines) to the medical necessity of cardiac surveillance.

Specify the clinical relevance of the history to the current presenting problem.

Example: The patient presents with persistent cytopenia. Note personal history of chemotherapy (Z92.21) with alkylating agents for ovarian cancer three years ago. Evaluation includes a CBC with differential to rule out therapy-related myelodysplastic syndrome (t-MDS). Complexity of history significantly increases the level of medical decision-making.

Billing Focus: The documentation justifies the ordering of complex lab work based on the specific toxicity profile of alkylating agents.

Address the presence or absence of late effects during every surveillance encounter.

Example: Follow-up for history of chemotherapy (Z92.21) for pediatric ALL. Patient is now 24 years old. Physical exam focuses on secondary malignancy screening and endocrine function. No signs of hypogonadism or growth hormone deficiency at this time. Plan: Annual metabolic panel and thyroid screening.

Billing Focus: Specifies the 'Personal History' status to prevent denial of screening labs often restricted to active cancer patients.

Use Z92.21 to support the medical necessity of long-term immunosuppression monitoring.

Example: Patient with personal history of high-dose chemotherapy and autologous stem cell transplant (Z92.21). Now 2 years post-treatment for multiple myeloma. Currently presenting with a routine upper respiratory infection. Due to history of intensive chemotherapy, I am treating with a lower threshold for secondary bacterial infection and ordering a chest X-ray to rule out pneumonia.

Billing Focus: The history code Z92.21 justifies a more aggressive diagnostic approach for a common symptom.

Relevant CPT Codes

Related Diagnoses

Hierarchy